KINIKSA PHARMACEUTICALS INTE
KNSANASDAQTrading Snapshot
- Day Range
- $87.54 – $95.26
- 52-Week Range
- $24.85 – $95.28
- Volume (shares)
- 1,704,244
- Avg Volume (shares)
- —
- Shares Outstanding
- 78.0M
- Next Earnings
- 2027-02-22
Fundamentals Snapshot
- Annual Revenue
- $678M
- Last Q Revenue
- $286M
- P/E Ratio
- 66.6
- P/S Ratio
- 7.9x
- EPS (TTM)
- $1.40
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +9.2%
KINIKSA PHARMACEUTICALS INTE
KNSA
StockOtter · stockotter.spaceAbout KINIKSA PHARMACEUTICALS INTE
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Kiniksa Pharmaceuticals: 3 Key Takeaways for Long-Term Investors
Kiniksa raised 2026 revenue guidance to over $1.045 billion. ARCALYST penetration among multiple recurrence patients reached 23%.
What Kiniksa Pharmaceuticals International (KNSA) Said on Its Q3 Earnings Call
Kiniksa Pharmaceuticals International NASDAQ: KNSA raised its full-year 2026 revenue guidance after reporting third-quarter ARCALYST revenue growth of 58% year over year, as the company continued to expand use of the dru
Kiniksa Pharmaceuticals International, plc (KNSA) Q3 2026 Earnings Call Transcript
Kiniksa Pharmaceuticals International, plc (KNSA) Q3 2026 Earnings Call Transcript
Kiniksa Pharmaceuticals International, plc (KNSA) Q3 Earnings and Revenues Surpass Estimates
Kiniksa Pharmaceuticals International, plc (KNSA) came out with quarterly earnings of $0.56 per share, beating the Zacks Consensus Estimate of $0.32 per share. This compares to earnings of $0.23 per share a year ago.
Kiniksa Pharmaceuticals Reports Third Quarter 2026 Financial Results and Recent Portfolio Execution
– ARCALYST ® (rilonacept) Q3 2026 net product revenue of $286.0 million, representing ~58% year-over-year growth – – ARCALYST 2026 expected net product revenue increased to $1.045 - $1.050 billion – – KPL-387 pivotal Pha
Kiniksa Pharmaceuticals to Report Third Quarter 2026 Financial Results on October 27, 2026
LONDON, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, October 27, 2026 at 8:30 a.m. Eastern T